A study to evaluate Chemotherapy Plus Osimertinib against Chemotherapy Plus Placebo in patients with non-small cell lung cancer (NSCLC)

Trial Identifier: D5162C00042
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: September 2021
Primary Completion Date: October 2024
Study Completion Date: June 2026
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
CN Beijing, CN, 100005
CN Beijing, CN, 100142
CN Ganzhou, CN, 341099
CN guangzhou, CN, 510080
CN Jinan, CN, 250013
CN shenyang, CN, 110001
CN Tianjin, CN, 300060
CN Zhengzhou City, CN, 450008
DE Berlin, DE, 12351
DE Hannover, DE, 30625
DE Köln, DE, 51109
DE Köln, DE, 50937
DE München, DE, D-80336
ES Alicante, ES, 03010
ES Barcelona, ES, 08907
ES Córdoba, ES, 14004
ES León, ES, 24071
ES Málaga, ES, 29010
ES Murcia, ES, 30008
ES Oviedo, ES, 33011
ES Palma de Mallorca, ES, 07010
ES Sevilla, ES, 41013
ES Valencia, ES, 46010
IL Beer Sheva, IL, 84101
IL Jerusalem, IL, 9103102
IL Jerusalem, IL, 9112001
IL Kfar Saba, IL, 4428164
IL Tel Aviv, IL, 6423906
IL Tel Hashomer, IL, 52621
IT Firenze, IT, 50134
IT Meldola, IT, 47014
IT Messina, IT, 98158
IT Napoli, IT, 80131
IT Padova, IT, 35128
IT Roma, IT, 00168
IT Terni, IT, 05100
IT Verona, IT, 37124
US, MA Boston, MA, US, 02114
US, MD Silver Spring, MD, US, 20910